Pharmaceuticals

Alli Oops! A Real Mess for Drug Campaign

GlaxoSmithKline (GSK) has launched a $150 million promotion campaign for its over-the-counter (OTC) weight loss drug, Alli. But not all media coverage is up-beat about what is a lower-dose version of Roche's prescription only drug, Xenical.

No

FDA's Flack Attack

Several members of Congress are asking about conflicts of interest at the U.S. Food and Drug Administration after an FDA spokesman, who previously worked as a public relations representative for pharmaceutical companies, used agency email to attack the research of an independent scientist. Douglas Arbesfeld, a senior communications consultant to the FDA, sent an email to reporters attacking Dr.

No

FDA Rejects Sunlight

In the wake of the latest study showing heart attack risk in an FDA-approved drug, there have been increased calls for greater transparency of clinical trial results. What does the U.S. Food and Drug Administration think about requiring companies to publicly release all of their trial results?

No

Unhealthy Secrecy

The chairperson of the Best Medicines Coalition (BMC), Louise Binder, recently appeared before the Canadian parliament's health committee to argue the case for patients gaining access to newer and more expensive drugs. When asked who funded BMC, Binder told the committee that half its funding came from the government agency, Health Canada, and the remainder was from the drug industry.

No

Crisis Management "Gold Standard" Actually Tinny

As many speeches, magazines and books have done previously, the current issue of Fortune magazine calls Johnson & Johnson's (J&J's) response to the 1982 Tylenol capsule poisoning deaths "the gold standard in crisis control." O'Dwyer's PR Daily writes that "the Tylenol story, as comm

No

More Outsourced Science Raises More Questions

"The public interest and the private interest aren't always the same thing," said Rep. Dennis Kucinich (D-Ohio), as Congress prepares to investigate "possible conflicts of interest involving medical research firms such as the Constella Group." The U.S.

No

Thailand Pays for a PR Coup

Thailand's unelected interim government, which was installed after a military coup in September 2006, is "increasingly unpopular at home" and "under attack abroad for overriding drug patents," reports Reuters. So, according to former army chief turned Prime Minister Surayud Chulanont, Thailand will "spend $600,000 on a three-month public relations campaign" to improve the government's poor image. "The money isn't much, but we have to do what we have to do," said Chulanont.

No

Pages

Subscribe to Pharmaceuticals